NASDAQ$HUMA
Humacyte Inc · Q2 2024 earnings
Q2 2024 earnings · · Before market open · Investor relations
Briefing
Humacyte Inc reported no revenue and a net loss of $56.7 million for Q2 2024.
The company continued to incur significant operating losses driven by research and development expenses for its ATEV product candidates. Cash and cash equivalents increased to $93.6 million following a public offering and additional funding under the revenue interest purchase agreement. The FDA extended its review timeline for the BLA in vascular trauma.
- Revenue remained zero as the company is pre-commercial with no approved products.
- Net loss widened to $56.7 million from $22.7 million in Q2 2023 due to higher R&D spend and non-cash fair value adjustments.
- Cash position strengthened to $93.6 million after raising $43 million in equity and receiving $20 million from the Purchase Agreement.
- FDA extended review of BLA for ATEV in vascular trauma beyond the original August 10, 2024 PDUFA date.
Headline financials
Revenue & EPS history
Humacyte · Revenue · Quarterly
$0
Forward guidance
The company is advancing clinical programs and awaiting further FDA feedback on the vascular trauma BLA while preparing for potential commercialization.
Tailwinds
- Positive topline data from V007 Phase 3 AV access trial announced in July 2024.
- Additional $40 million available under Purchase Agreement upon BLA approval.
Headwinds
- FDA requires additional time to complete BLA review for vascular trauma indication.
- Substantial doubt about ability to continue as going concern without additional capital or approval.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
+5.1%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+3.5%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+37.0%
Q2 2023
Best reaction
-30.1%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q1 2026 | +22.9% | -1.5% | +15.2% | |
| Q4 2025 | -15.1% | -25.1% | -33.0% | |
| Q3 2025 | -3.2% | -11.7% | +2.3% | |
| Q2 2025 | -30.1% | -24.2% | -40.3% | |
| Q1 2025 | +19.5% | +23.8% | +25.4% | |
| Q4 2024 | -2.5% | -27.4% | -28.4% | |
| Q3 2024 | +4.9% | +1.5% | -8.2% | |
| Q1 2024 | +21.2% | +43.1% | +60.8% | |
| Q4 2023 | -12.8% | -13.9% | +2.8% | |
| Q3 2023 | +7.3% | +9.1% | +27.9% | |
| Q2 2023 | +37.0% | +8.9% | +19.0% | |
| Q1 2023 | -6.1% | -2.5% | +1.1% | |
| Q4 2022 | +4.9% | -1.3% | +7.1% | |
| Q3 2022 | +2.2% | -5.4% | -4.5% | |
| Q2 2022 | +8.6% | +9.1% | +2.5% | |
| Q1 2022 | -9.5% | -12.7% | -18.8% | |
| Q4 2021 | +14.1% | +12.2% | +16.5% | |
| Q2 2021 | +14.1% | +12.2% | +16.5% | |
| Q3 2021 | +9.0% | +18.4% | +4.0% | |
| Q1 2021 | +0.0% | +0.0% | +4.9% | |
| Q4 2020 | +21.2% | +28.4% | +1.5% | |
| Q3 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro